Level B· Emerging clinical evidence with positive signalsClinical TrialPubMed

Meaningful changes in physical function and pain in patients with knee osteoarthritis.

Tang X., Lai JS., Kang SK., Peipert JD.

Clinical Trial with a reported sample of 252 on Knee Osteoarthritis, Osteoarthritis, published in J Patient Rep Outcomes (2025) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
J Patient Rep Outcomes (2025)
Country
Germany
Reported sample size
252
Source database
PubMed
PMID
41003871
DOI
10.1186/s41687-025-00941-x
NCT
NCT03990805

Abstract (original English)

BACKGROUND: This study aims to establish meaningful within-person change (MWPC) thresholds for the Total Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC®), its Physical Function (PF) subscale, and the Visual Analog Scale (VAS) for Pain, in patients with knee osteoarthritis (OA). A secondary objective is to evaluate the effectiveness of a single injection of autologous culture-expanded adipose tissue-derived mesenchymal stem cells (ADMSCs) using these thresholds. METHODOLOGY: The study included 252 patients with knee OA enrolled in a clinical trial. An anchor-based predictive modeling approach, using KOOS-12, SF-36, and IKDC scores with literature-based cut-offs, was applied to determine MWPC thresholds for WOMAC and VAS Pain. MWPC thresholds were derived from both the ADMSCs injection and Control (autoserum) groups at 3- and 6-month follow-ups. Treatment effectiveness was assessed by comparing MWPC range with between-group differences and within-person changes. RESULTS: MWPC thresholds were identified as follows: 5–17 points for WOMAC Total, 4–12 points for WOMAC PF, and 8–14 points for VAS Pain (all on 0–100 scales). The adjusted differences between the ADMSCs injection and Control (autoserum) groups of all three measures (3 months: WOMAC Total 5.9, WOMAC Function 4.2, VAS Pain 8.6; 6 months: WOMAC Total 9.3, WOMAC Function 6.5, VAS Pain 11.7) were within

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
HumansOsteoarthritis, KneeFemalePain MeasurementMaleAgedMiddle AgedMesenchymal Stem Cell TransplantationTreatment OutcomePatient Reported Outcome Measures

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research